ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)

Data ReadoutpositiveantimiR-23bPositive

AI Analysis

Summary

ARTHEx Biotech published preclinical data demonstrating that antimiR-23b delivered systemically crosses into the brain, corrects disease biology, and improves behavioral symptoms in a myotonic dystrophy type 1 model. The results highlight the potential of the BOOST-ON platform to address CNS manifestations of DM1.

Outcome Details

Systemic delivery of antimiR-23b reached the brain, corrected disease biology, and improved behavior in preclinical DM1 model

Importance:4/10

Sentiment:

0.70

preclinical_dataCNSmyotonic_dystrophyantimiRBOOST-ON_platform

Related Companies

$BNN.DE $TRAX

Read the original article

Published by PR Newswire Clinical Trials on July 23, 2026 7:00 AM

Read Original